Dimensional Fund Advisors LP Takes Position in Corvus Pharmaceuticals, Inc. (CRVS)

Dimensional Fund Advisors LP bought a new position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 26,443 shares of the company’s stock, valued at approximately $320,000. Dimensional Fund Advisors LP owned about 0.13% of Corvus Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRVS. JPMorgan Chase & Co. grew its position in shares of Corvus Pharmaceuticals by 116.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 332,634 shares of the company’s stock valued at $4,025,000 after buying an additional 178,658 shares during the last quarter. Jennison Associates LLC grew its position in shares of Corvus Pharmaceuticals by 87.4% during the 2nd quarter. Jennison Associates LLC now owns 1,019,013 shares of the company’s stock valued at $12,330,000 after buying an additional 475,164 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Corvus Pharmaceuticals by 37.1% during the 2nd quarter. Vanguard Group Inc. now owns 373,512 shares of the company’s stock valued at $4,520,000 after buying an additional 101,013 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Corvus Pharmaceuticals by 81.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 28,978 shares of the company’s stock valued at $351,000 after buying an additional 13,023 shares during the last quarter. Finally, Nationwide Fund Advisors grew its position in shares of Corvus Pharmaceuticals by 284.9% during the 2nd quarter. Nationwide Fund Advisors now owns 76,813 shares of the company’s stock valued at $929,000 after buying an additional 56,856 shares during the last quarter. 83.47% of the stock is owned by institutional investors.

In other news, CEO Richard A. Md Miller bought 10,000 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was purchased at an average price of $10.79 per share, for a total transaction of $107,900.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 46.40% of the stock is currently owned by corporate insiders.

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) opened at $10.69 on Thursday. Corvus Pharmaceuticals, Inc. has a 1 year low of $8.27 and a 1 year high of $22.14.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings data on Thursday, November 2nd. The company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. analysts forecast that Corvus Pharmaceuticals, Inc. will post -2.82 earnings per share for the current year.

A number of equities research analysts recently weighed in on CRVS shares. Zacks Investment Research raised shares of Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Monday, August 28th. Credit Suisse Group raised shares of Corvus Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $14.00 price objective for the company in a research report on Wednesday, August 23rd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Corvus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $20.25.

WARNING: “Dimensional Fund Advisors LP Takes Position in Corvus Pharmaceuticals, Inc. (CRVS)” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.com-unik.info/2017/12/07/dimensional-fund-advisors-lp-takes-position-in-corvus-pharmaceuticals-inc-crvs.html.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Institutional Ownership by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

What are top analysts saying about Corvus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corvus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit